Cargando…
Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879886/ https://www.ncbi.nlm.nih.gov/pubmed/29557364 http://dx.doi.org/10.4103/1673-5374.226389 |
| _version_ | 1783311073556824064 |
|---|---|
| author | Souchet, Benoit Audrain, Mickael Billoir, Baptiste Lecanu, Laurent Tada, Satoru Braudeau, Jérôme |
| author_facet | Souchet, Benoit Audrain, Mickael Billoir, Baptiste Lecanu, Laurent Tada, Satoru Braudeau, Jérôme |
| author_sort | Souchet, Benoit |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5879886 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Medknow Publications & Media Pvt Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58798862018-04-06 Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? Souchet, Benoit Audrain, Mickael Billoir, Baptiste Lecanu, Laurent Tada, Satoru Braudeau, Jérôme Neural Regen Res Perspective Medknow Publications & Media Pvt Ltd 2018-02 /pmc/articles/PMC5879886/ /pubmed/29557364 http://dx.doi.org/10.4103/1673-5374.226389 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| spellingShingle | Perspective Souchet, Benoit Audrain, Mickael Billoir, Baptiste Lecanu, Laurent Tada, Satoru Braudeau, Jérôme Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_full | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_fullStr | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_full_unstemmed | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_short | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_sort | is it time to rethink the alzheimer's disease drug development strategy by targeting its silent phase? |
| topic | Perspective |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879886/ https://www.ncbi.nlm.nih.gov/pubmed/29557364 http://dx.doi.org/10.4103/1673-5374.226389 |
| work_keys_str_mv | AT souchetbenoit isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT audrainmickael isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT billoirbaptiste isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT lecanulaurent isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT tadasatoru isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT braudeaujerome isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase |